Is Evexia Lifecare overvalued or undervalued?

Oct 07 2025 08:04 AM IST
share
Share Via
As of October 6, 2025, Evexia Lifecare is considered overvalued with a PE ratio of 210.26 and a year-to-date return of -43.19%, significantly underperforming compared to its peers and the Sensex.
As of 6 October 2025, Evexia Lifecare's valuation grade has moved from very expensive to expensive. The company is currently overvalued, with a PE ratio of 210.26, an EV to EBITDA ratio of 205.54, and a price to book value of 0.84. In comparison, peers such as Castrol India and Gulf Oil Lubricants show significantly lower PE ratios of 20.99 and 16.44, respectively, indicating that Evexia Lifecare is trading at a premium relative to its industry counterparts.

Additionally, Evexia Lifecare has experienced a substantial decline in stock performance, with a year-to-date return of -43.19%, contrasting sharply with the Sensex's gain of 4.67% over the same period. This further reinforces the notion that the company's current valuation does not align with its financial performance and market trends.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News